Auxly Cannabis Group Inc.

TSX:XLY.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.53 +0.00%

+$0.00 today

Market cap
$364.42M
Beta
1.16
P/E (TTM)
7.3
EPS (TTM)
$0.02
52W Low $0.08High $0.19

Volume 0.13M

Average 0.71M

XLY.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Auxly Cannabis Group Inc.TSX: XLY.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows in line with its trailing trend

Q1 FY2026 revenue of CA$39.75M rose 21.7% year over year, behind the +22.2% change in trailing-twelve-month revenue. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of CA$184.65M (+21.9%) for the fiscal year ending Dec 2026, a slowdown from the +23.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$39.75M-0.9% QoQ
Last fiscal yearDec 2025
CA$151.48M+23.8% YoY
LTMMar 2026
CA$158.57M+22.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.7%+5.9%-15.8 pp
1 year+23.8%+21.9%-1.9 pp
3-year CAGR+17.0%+14.8%-2.3 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

CAD · from the income statement

Latest · FY2025
151.48M CAD
Year-over-year change
+23.8%
4-year CAGR
+15.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How XLY.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +22.2% is the highest of 3, against a peer median of +0.2%.
  • Over three fiscal years its annual growth of +17.0% compares with a peer median of -1.9%.
XLY.TO Competitors
Revenue for XLY.TO and competitors
Company Period LTM YoY 3-year CAGR
CRRX.TOCareRx CorporationLTM Mar 2026CA$374.61M CAD+2.2%-1.0%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$158.57M CAD+22.2%+17.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$55.76M USD-1.8%-2.8%
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$0 CAD——
Peer median (excluding XLY.TO) —+0.2%-1.9%

Competitors are the stored peer set for XLY.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue83.83M94.47M101.08M122.33M151.48M
Cost of Revenue64.54M77.96M79.8M62.4M64.74M
Gross Profit19.29M16.51M21.28M59.93M86.74M
Gross Margin23.0%17.5%21.1%49.0%57.3%
Research & Development298K292K497K00
Selling, General & Admin45.42M50.38M40.28M40.73M49.07M
Operating Expenses58.23M65.49M47.23M45.22M54.07M
Depreciation & Amortization14.27M20.18M11.21M10.28M11.45M
EBITDA(18.3M)(94.79M)(10.89M)24.38M50.31M
EBITDA Margin-21.8%-100.3%-10.8%19.9%33.2%
Operating Income(38.94M)(48.98M)(25.95M)14.71M32.67M
Operating Margin-46.4%-51.8%-25.7%12.0%21.6%
Interest Income1.59M337K32K240K130K
Interest Expense17.67M21.58M25.65M14.46M6.34M
Other Income / Expenses(11.3M)(87.58M)(21.8M)(15.07M)(155K)
Income Before Tax(50.24M)(136.56M)(47.75M)(356K)32.52M
Pre-Tax Margin-59.9%-144.5%-47.2%-0.3%21.5%
Income Tax Expense(4.33M)(6.26M)(3.24M)15.99M(9.34M)
Net Income(33.74M)(130.29M)(44.51M)(16.35M)41.86M
Net Margin-40.2%-137.9%-44.0%-13.4%27.6%
EPS (Basic)(0.06)(0.15)(0.04)(0.01)0.03
EPS (Diluted)(0.06)(0.15)(0.04)(0.01)0.03
Weighted Avg Shares783.38M889.87M990.99M1.2B1.33B
Weighted Avg Shares (Diluted)783.38M889.87M990.99M1.2B1.59B

Auxly Cannabis Group Inc.

TSX:XLY.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.